^
    Back
    Association details:
    Biomarker:TERT promoter mutation + BRAF V600
    Cancer:Melanoma
    Drug Class:BRAF inhibitor +
    MEK inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Eur J Cancer
    Title:

    TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy

    Published date:
    01/01/2022
    Excerpt:
    In the pooled cohort of TERT promoter-mutant (N = 167) versus wild-type (N = 65) tumours, respectively, PFS was 8.9 versus 5.5 months, (HR = 0.62; 95%CI 0.45-0.87; P = 0.004), and OS was 33.6 versus 17.0 months, (HR = 0.51; 95%CI 0.35-0.75, P = 0.0001)....In patients with melanoma receiving BRAF/MEK-targeted therapies, TERT promoter mutations are associated with longer survival.
    DOI:
    10.1016/j.ejca.2021.11.009.